Precision Medicine in Oncology®

Entrectinib received its first regulatory approval, as Japan’s Ministry of Health, Labour and Welfare has approved the drug for the treatment of adult and pediatric patients with NTRK fusion–positive, advanced recurrent solid tumors.

Geoffrey Oxnard, MD, discusses testing error underlying liquid biopsy discordance, steps clinicians can take to optimize liquid biopsy, and where he sees this evolving in the treatment landscape for patients with cancer.

Toll-like receptors, a group of proteins that are components of innate immunity, are emerging as promising targets in a new wave of immunotherapies under development.

Vassiliki A. Papadimitrakopoulou, MD, professor of medicine, Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, discusses the utility of liquid biopsies in non–small cell lung cancer (NSCLC).

Sayeh Lavasani, MD, MS, discusses the application of gene assays in the management of patients with hormone receptor-positive breast cancer, as well as ongoing research in this space.

Aditya Bardia, MD, MPH, discusses the potential role of circulating tumor cells and circulating tumor DNA testing in patients with breast cancer.